HILLSTREAM BIOPHARMA INC (HILS)
US4327051011 - Common Stock
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) --...
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration...
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on...
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing...
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective...
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
Appointment to Enhance Board’s Expertise Across Investments, Business Development and Capital Markets...
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company...
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World...
Why Is Constellation Brands (STZ) Stock Down Today?
Constellation Brands (STZ) stock is falling on Friday after the beverage company revealed details of a senior note debt offering.
Why Is ENDRA Life Sciences (NDRA) Stock Down 16% Today?
ENDRA Life Sciences (NDRA) stock is sliding lower on Friday after revealing details of its public offering for 862,500 shares.
Why Is Hillstream BioPharma (HILS) Stock Down 57% Today?
Hillstream BioPharma (HILS) stock is taking a beating on Friday after the company revealed plans for a public offering of its shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The biggest pre-market stock movers are a hot topic traders are going to want to know about with all the latest news on Friday!
Hillstream BioPharma Announces Pricing of Public Offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company...
Hillstream BioPharma proposes stock and warrants offering, shares fall 20% (NASDAQ:HILS)
Hillstream BioPharma (HILS) said Thursday it intends to offer to sell shares of its common stock, and/or pre-funded warrants in an underwritten public offering.
Hillstream BioPharma Announces Proposed Public Offering
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company...
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
OncoBay Clinical is a boutique clinical research organization (CRO) that is a subsidiary of the Moffitt Cancer Center and has extensive experience in...